AJES Pharmaceuticals, LLC – Pharmaceutical Company – Copiague, New York #asia #pharma

Posted On Nov 24 2016 by

#pharmaceutical companies in new york # Contact Information Connect: Welcome to AJES Pharmaceuticals, LLC AJES Pharmaceuticals, LLC is a licensed and registered pharmaceutical contract manufacturing company located in Copiague, New York. We are one of fastest growing private label manufacturers in the state and country. At AJES Pharmaceuticals, LLC. we offer a wide range of services for all your pharmaceutical, vitamins, Minerals, Herbal, Sports Nutrition, Protein and Specialty Neutraceutical Powders needs. We employ the highest standards when it comes to our products. It is our aim to surpass known brands in order to be a known alternative source for our …


Hanford Pharmaceuticals #medley #pharma

Posted On Nov 24 2016 by

#pharmaceutical companies in new york # A Veterinary Leader With a rich heritage dating back to the mid-1800’s, Hanford Pharmaceuticals has been a world leader in providing quality veterinary products to American food producers. Hanford Pharmaceuticals is committed to America’s food producers by offering quality veterinary products that maintain the health and quality of life of herds. Throughout the United States veterinarians and producers rely on Hanford’s outstanding products to improve the productivity of their livestock. Hanford’s mission is providing and maintaining superior quality veterinary products to our customers and to ensure their satisfaction. Our future has never been more …


Syros Pharmaceuticals #pharmacy #companies

Posted On Nov 24 2016 by

#pharmaceutical companies in boston # Advancing a new wave of genomic medicines Advancing a new wave of genomic medicines Working together to transform patients’ lives through the creation of novel gene control medicines Working together to transform patients’ lives through the creation of novel gene control medicines Based on the disruptive science of gene control Based on the disruptive science of gene control GENE CONTROL Researchers have long believed that alterations in non-coding regions of DNA, which account for 98% of the genome, play a key role in driving disease. However, the scientific community has lacked the tools to study …


Our Services to the Pharmaceuticals and Life Sciences Industry, PwC Canada #santaris #pharma

Posted On Nov 24 2016 by

#pharmaceutical companies in canada # Pharmaceuticals and Life Sciences Helping the business of health by improving the health of business Is it any surprise that Canada’s life sciences and pharmaceutical industry receives one out of every four dollars of venture capital investment? After all, an aging Canadian population has significantly increased demand for health-related products and treatment, and the sector is working hard to keep up. With the global pharmaceutical market predicted to double to $1.8 trillion by 2020, there is a lot at stake for Canadian players in this sector. Yet there are unique challenges facing our life sciences …


AVANIR Pharmaceuticals Signs Collaborative Research and Development Agreement With Chinese Pharmaceutical Company #app #pharma

Posted On Nov 24 2016 by

#chinese pharmaceutical companies # AVANIR Pharmaceuticals Signs Collaborative Research and Development Agreement With Chinese Pharmaceutical Company Agreement Is Significant Step Toward Marketing Docosanol in China SAN DIEGO, Jan 16, 2002 /PRNewswire via COMTEX/ — AVANIR Pharmaceuticals (Amex: AVN) announced today the signing of a collaborative research and development agreement with Shanghai New Asiatic Pharmaceutical Company, Ltd. a division of Shanghai Pharmaceutical Co. Ltd. the largest state-owned pharmaceutical conglomerate in the People’s Republic of China. The agreement is considered a preliminary step in the process toward marketing AVANIR’s docosanol 10% cream in the People’s Republic of China, including Hong Kong and …


Martin Shkreli Resigns From Turing Pharmaceuticals #claris #pharma

Posted On Nov 24 2016 by

#pharmaceutical companies in nyc # The New York Times Martin Shkreli Resigns From Turing Pharmaceuticals By ANDREW POLLACK December 18, 2015 Martin Shkreli has resigned as chief executive of Turing Pharmaceuticals after his arrest on securities fraud charges, the company announced on Friday. Turing, a privately held company in New York, said that Ron Tilles. its chairman, would step in as interim chief executive. Mr. Tilles, who will remain chairman, has spent most of his career at securities firms and other financial service companies, according to the description of him on Turing’s website. But he was a founder and worked …


Working at Boehringer Ingelheim Pharmaceuticals #big #pharmaceutical #companies

Posted On Nov 23 2016 by

#bi pharma # Boehringer Ingelheim Pharmaceuticals I applied online. The process took 2+ months. I interviewed at Boehringer Ingelheim Pharmaceuticals (New York, NY). 3 part phone interview process. One with recruiter, one with hiring manager and one with hiring manager and hiring manager counterpart. The entire process took two months. Overall experience was okay, but certainly felt strung along at the end waiting for a final response. What about therapeutic areas are you challenged in? Answer Question Why are you looking to change jobs? Answer Question Tell me about the changing landscape of healthcare? Answer Question Boehringer Ingelheim Pharmaceuticals 2016-07-22 …


Arbor Pharmaceuticals #wuxi #pharma

Posted On Nov 23 2016 by

#pharma companies in usa # Improving Lives by Advancing Medicine Arbor Pharmaceuticals is an Atlanta, Georgia based specialty pharmaceutical company which markets prescription products for the cardiovascular, hospital, neuroscience, and pediatric markets. Arbor also has several branded prescription products filed with the FDA and in late stage development. In addition, the company has multiple generic prescription products on the market, filed with the FDA, and in various stages of development. We believe that our strongest asset is our people and have hired industry veterans with pharmaceutical knowledge and experience across most therapeutic areas encompassing all stages of development, manufacturing and …


Mylan Pharmaceuticals Inc #pharma #products

Posted On Nov 23 2016 by

#mylan pharma # Mylan Pharmaceuticals Inc. Latest Drug Information Updates Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent. Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated. Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the. Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A. Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB). Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing. More. Was this page helpful? …


Clinical Data Completes Acquisition of Avalon Pharmaceuticals #gea #pharma #systems

Posted On Nov 22 2016 by

#avalon pharma # Clinical Data Completes Acquisition of Avalon Pharmaceuticals May 28, 2009 04:06 PM Eastern Daylight Time NEWTON, Mass.–( BUSINESS WIRE )–Clinical Data, Inc. (Nasdaq: CLDA) today announced the completion of its acquisition of Avalon Pharmaceuticals, Inc. Clinical Data acquired Avalon through an all-stock transaction valued at approximately $10 million, based upon the 15-day volume weighted average price of $12.49 for Clinical Data s common stock through Monday, October 27, 2008, the date of the definitive merger agreement. As a result of the acquisition, the common stock of Avalon ceased trading at market close on May 28, 2009. As …